Discounted Cash Flow (DCF) Analysis Levered

Mithra Pharmaceuticals SA (MITRA.BR)

0.526 €

+0.01 (+0.96%)
All numbers are in Millions, Currency in USD
Stock DCF: -1,326.49 | 0.526 | overvalue

Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 57.8896.529.0322.6767121.05218.71395.16713.971,289.99
Revenue (%)
Operating Cash Flow 3.54-46.83-80.03-74.39-56.82-324.79-586.83-1,060.27-1,915.69-3,461.23
Operating Cash Flow (%)
Capital Expenditure -10.10-15.45-16.23-21.18-25.66-83.51-150.88-272.61-492.55-889.93
Capital Expenditure (%)
Free Cash Flow -6.56-62.28-96.25-95.57-82.48-408.30-737.71-1,332.89-2,408.24-4,351.16

Weighted Average Cost Of Capital

Share price $ 0.526
Beta 0.543
Diluted Shares Outstanding 49.06
Cost of Debt
Tax Rate -419.33
After-tax Cost of Debt 7.44%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.722
Total Debt 228.43
Total Equity 25.81
Total Capital 254.23
Debt Weighting 89.85
Equity Weighting 10.15
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 57.8896.529.0322.6767121.05218.71395.16713.971,289.99
Operating Cash Flow 3.54-46.83-80.03-74.39-56.82-324.79-586.83-1,060.27-1,915.69-3,461.23
Capital Expenditure -10.10-15.45-16.23-21.18-25.66-83.51-150.88-272.61-492.55-889.93
Free Cash Flow -6.56-62.28-96.25-95.57-82.48-408.30-737.71-1,332.89-2,408.24-4,351.16
WACC
PV LFCF -380.28-639.91-1,076.82-1,812.04-3,049.23
SUM PV LFCF -6,958.28

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 7.37
Free cash flow (t + 1) -4,438.19
Terminal Value -82,647.78
Present Value of Terminal Value -57,918.38

Intrinsic Value

Enterprise Value -64,876.66
Net Debt 200.14
Equity Value -65,076.80
Shares Outstanding 49.06
Equity Value Per Share -1,326.49